Roche fined for breaching direct to consumer advertising ban and publishing unbalanced advertisementsBMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39542.583669.DB (Published 10 April 2008) Cite this as: BMJ 2008;336:792
- Bob Burton
Roche Products Australia has been fined a total of $A110 000 (£50 000; €64 000; $101 000) for breaching the drug industry’s self regulatory code of conduct by distributing three media releases that, despite a ban on direct to consumer drug advertising, promoted prescription drugs to the public.
The releases also promoted the use of approved drugs for unapproved indications and were unbalanced, omitting some of the risks associated with the drugs.
The complainant was the drug company GlaxoSmithKline Australia. It complained that Roche had published 21 media releases promoting the use of unapproved prescription drugs or approved drugs for unapproved indications. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial